THE FUTURE IS HERE

Meet Azure™ Pacemaker with BlueSync™ Technology
THE FUTURE IS HERE

Meet Azure™ Pacemaker with BlueSync™ Technology

UNMATCHED FEATURE SUITE

- Exclusive algorithms to manage atrial fibrillation (AF) in pacemaker patients
- Reduce unnecessary RV pacing with MVP™ feature
- Improved longevity — updated hardware architecture optimizes circuitry (to reduce current drain)
- Unmatched MRI access — 1.5T and 3T full body scanning

REIMAGINED CONNECTIVITY

BlueSync™ technology that enables tablet-based programming and app-based remote monitoring

STREAMLINED WORKFLOWS

- Manage alerts of clinically relevant events with additional CareAlert™ notifications
- MyCareLink Heart™ mobile app is designed to increase clinic efficiencies through patient compliance

1 in 3 CIED patients will develop new onset AF within the first 2.5 years of implant

- Increases the risk of heart failure greater than 3-FOLD
- 5-FOLD increase in ischemic stroke risk for AF patients

Atrial Fibrillation (AF) Is Prevalent and Clinically Challenging

DETECT

Highest published AF episode detection accuracy (PPV)*†4-7

95–96% AF episode detection accuracy (PPV)

4-7

REDUCE

Exclusive algorithms demonstrated to reduce the risk and duration of AF

36% relative reduction in AT/AF episodes ≥ 7 days with Reactive ATP™ Algorithm†8

* A controlled, head-to-head study evaluating the comparative performance of device algorithms has not been done. AF detection accuracy rates determined from independent clinical trials are presented for reference.

† Detection accuracy is compared using PPV, which is the percentage of all AT/AF episodes detected by the individual device detection algorithm that were adjudicated as true AT/AF.
Atrial Fibrillation (AF) Is Prevalent and Clinically Challenging

1 in 3 CIED patients will develop new onset AF within the first 2.5 years of implant¹

Increases the risk of heart failure greater than 3-FOLD²

5-FOLD increase in ischemic stroke risk for AF patients³

Exclusive Algorithms to Manage AF in Patients

DETECT

Highest published AF episode detection accuracy (PPV)⁴-⁷

95–96% AF episode detection accuracy (PPV)⁵-⁷

REDUCE

Exclusive algorithms demonstrated to reduce the risk and duration of AF

36% relative reduction in AT/AF episodes ≥ 7 days with Reactive AT/AF™ Algorithm¹⁸

UNMATCHED FEATURE SUITE

Exclusive algorithms to manage atrial fibrillation (AF) in pacemaker patients

Reduce unnecessary RV pacing with MVP™ feature

Improved longevity — updated hardware architecture optimizes circuitry (to reduce current drain)

Unmatched MRI access — 1.5T and 3T full body scanning

REIMAGINED CONNECTIVITY

BlueSync™ technology that enables tablet-based programming and app-based remote monitoring

STREAMLINED WORKFLOWS

Manage alerts of clinically relevant events with additional CareAlert™ notifications

MyCareLink Heart™ mobile app is designed to increase clinic efficiencies through patient compliance

*A controlled, head-to-head study evaluating the comparative performance of device algorithms has not been done. AF detection accuracy rates determined from independent clinical trials are presented for reference.

†Detection accuracy is compared using PPV, which is the percentage of all AT/AF episodes detected by the individual device detection algorithm that were adjudicated as true AT/AF.
UNMATCHED FEATURE SUITE

Exclusive Algorithms to Manage AF in Patients

Reduce duration of AF with Reactive ATP
Reactive ATP provides an opportunity to terminate an ongoing AF episode by delivering ATP during those times when the rhythm has organized and/or slowed.

Analysis design
An analysis design of 8,032 patients in the Medtronic CareLink™ database assessed the impact of Reactive ATP across pacemakers, ICDs, and CRT devices.

RESULTS

Reactive ATP is associated with a reduction in the duration of AT/AF:
- ≥ 1 day by 19%
- ≥ 7 days by 36%
- ≥ 30 days by 44%

36% reduced risk of persistent AF

Simple programming nominals updated to MINERVA settings.

*Compared to matched control group; matched components included age, sex, baseline AF and percent VP, pacing mode, and device type.
Reduce Unnecessary RV Pacing\textsuperscript{10} with MVP Feature

**Now updated with the option to control maximum AV interval**

- RV pacing is associated with an increased risk of HF hospitalization.\textsuperscript{11}
- RV pacing is associated with a 1% increase in risk of AF for each 1% increase in cumulative RV pacing.\textsuperscript{11}
- MVP algorithm reduces unnecessary RV pacing by 99%.\textsuperscript{10}

---

**RESULTS**

Reactive ATP is associated with a reduction in the duration of AF:\textsuperscript{8}

- \(\geq 1\) day by 19%
- \(\geq 7\) days by 36%
- \(\geq 30\) days by 44%

---

**Unmatched Feature Suite**

* Compared to matched control group; matched components included age, sex, baseline AF and percent VP, pacing mode, and device type.
With Azure MRI, Patients Have Access to 1.5T and 3T Full Body Scanning.*

Built to be scanned SureScan™ devices were specifically engineered for the MRI environment, with enhancements that ensure patient safety during an MRI scan.*

Scanning conditions are simple: no MRI exclusion zone, no patient height restriction, no MRI duration restriction.13

UNMATCHED FEATURE SUITE

Improved Longevity

Updated hardware architecture optimizes circuitry to reduce current drain and improve longevity.12

15.8 YEARS*
Azure XT SR MRI

13.7 YEARS†
Azure XT DR MRI

12.7 YEARS*
Advisa SR MRI™

10.8 YEARS†
Advisa DR MRI™

*Projected service life estimates assume device configuration at VVI 50%, 2.5V, 500 Ohm lead impedances, Pre-storage EGM off. Projected service life estimates are based on accelerated battery discharge data and device modeling. The values calculated based on this information should not be interpreted as precise numbers. Individual patient results may vary based on their specific programming and experience.

†Projected service life estimates assume device configuration at MVP 50% AP, 5% VP, 2.5V in both chambers, 500 Ohm lead impedances, Pre-storage EGM off. Projected service life estimates are based on accelerated battery discharge data and device modeling. The values calculated based on this information should not be interpreted as precise numbers. Individual patient results may vary based on their specific programming and experience.

* For a complete list of approved device and lead combinations, please visit mrisurescan.com.

+24%
+27%
UNMATCHED MRI ACCESS

With Azure MRI, Patients Have Access to 1.5T and 3T Full Body Scanning.¹³

Built to be scanned

- SureScan™ devices were specifically engineered for the MRI environment, with enhancements that ensure patient safety during an MRI scan.⁹
- Scanning conditions are simple: no MRI exclusion zone, no patient height restriction, no MRI duration restriction.¹³

¹For a complete list of approved device and lead combinations, please visit mrisurescan.com.
REIMAGINED CONNECTIVITY

BlueSync Technology
Azure with BlueSync technology enables secure, wireless communication.

Security Measures
BlueSync technology security was designed to protect the device, patient data, and connectivity.

Device Protection
- Pacemaker doesn’t accept programming from unauthorized sources.
- Device not connected to internet.
  Devices do not have an IP address, unlike other connected consumer products.

Data Privacy
End-to-end encryption
Data are encrypted in the pacemaker using NIST* government standard for security before being transmitted to the CareLink network.

Key Components of BlueSync Technology

Bluetooth® Low Energy
enabled to securely communicate with Bluetooth Low Energy smartphones or tablets.

Encryption Technology
Data are encrypted in the pacemaker using NIST* standard encryption.

High-density Integrated Circuit
reduces current drain for increased longevity.

Please go to medtronic.com/security for up-to-date security information.

*NIST: National Institute of Standards and Technology.
MyCareLink Heart Mobile App

Patients can now use their smartphone to automatically transfer device data via the MyCareLink Heart mobile app, even outside the home (where cellular or Wi-Fi connectivity is available).*

- **My Heart Device**
  - Displays battery longevity, implant date, heart device name, serial number, and patient’s clinic information.

- **Physical Activity**
  - The app uses data from patient’s heart device to create daily, weekly, and monthly views of physical activity.

- **My Transmissions**
  - Has information about transmissions sent from a patient’s heart device to their clinic.

- **Education**
  - Provides information about living with a heart device.

- **Connectivity Status**
  - Green check mark confirms Bluetooth® is ON and the app was connected recently.

Patients are required to keep their smartphone/tablet up to date to use the app.

* Please visit MCLHeart.com for a list of compatible smartphones and tablets.

Alternative Monitoring Option
MyCareLink Relay Home Communicator

MyCareLink Relay offers a monitoring alternative to patients who prefer not to use a smartphone.

- No manual pairing required
- Requires little to no user interaction

MyCareLink Relay must be plugged in and patients must be within communication range for successful transmissions. Requires Wi-Fi or cellular connection.
STREAMLINED WORKFLOWS

Timely Alerts of Clinically Relevant Events\textsuperscript{14,15}

Time to a clinical decision was \textit{\sim7x faster} with the use of Medtronic CareAlert notifications compared to standard office follow-up.\textsuperscript{16}

\textbf{CareAlert notifications can be programmed and viewed only by the clinician:}

- AT/AF Burden Notification
- Lead Impedance
- Low Battery Voltage @ RRT
- VT Episodes
- Fast V. Rate during AT/AF
- Capture Management™
- % V. Pacing

\textbf{Wireless alerts can now be transmitted via Bluetooth using the MyCareLink Heart mobile app, providing patient monitoring — even outside the home.}
MyCareLink Heart Mobile App

MyCareLink Heart mobile app was designed to offer the following benefits:

**Patient Engagement Promotes Patient Satisfaction**

- Integrate remote monitoring into your patient's daily life using a patient-owned smartphone and eliminate the need for a bedside monitor.
- Provide patient peace of mind with the MyCareLink Heart app, which allows patients to view select data such as transmission status.
- Activated patients are significantly more likely to engage in healthy behaviors.

**Patient Compliance Results in Increased Clinic Efficiencies**

- Patient monitoring — even outside the home — helps deliver quality of care in line with HRS guidelines.
- Reduce clinic time spent on follow-up activities.
- Push notifications help patients stay connected, transmit on time, and verify that transmissions were sent.

**Upgradeability Sets the Foundation for Future Technologies**

Similar to consumer apps, as technology advances, so will MyCareLink Heart — throughout the life of the pacemaker.
Indications:

http://www.mrisurescan.com/. Any other combination may result in a hazard to the patient or environment. To verify that components are part of a SureScan system, visit surescan.medtronic.com. A SureScan device with appropriate SureScan lead(s), is required for use in the MR environment.

Medtronic SureScan pacing systems are MR conditional, and are designed to allow patients to undergo MRI under the specified conditions described in this labeling. The Azure DR MRI™ and Azure SR MRI™ SureScan™ systems are indicated to perform ATP therapy in patients with atrial tachyarrhythmias as such are designed to allow patients to undergo MRI under the specified conditions described in this labeling.

Medtronic, Medtronic logo, and Further, Together are trademarks of Medtronic. The Bluetooth® word mark is a registered trademark owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license. Apple and the Apple logo are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. “Other third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.

References


Brief Statements

The Azure DR MRI™ and Azure SR MRI™ SureScan™ systems are indicated for co-contraindicated implantation with another bradycardia device or with an implantable cardioverter defibrillator. Rate-responsive modes may be contraindicated in those patients who cannot tolerate pacing rates above the programmed Lower Rate. Dual chamber sequential pacing is contraindicated in patients with chronic or persistent supraventricular tachycardia, atrial fibrillation or flutter. Asynchronous pacing is contraindicated in the presence (or likelihood) of competition between paced and intrinsic rhythms. Single chamber atrial pacing is contraindicated in patients with an AV conduction disturbance. ATP therapy is contraindicated in patients with an accessory antegrade pathway.

Warnings and Precautions: Changes in a patient’s disease and/or medications may alter the efficacy of the device’s programmed parameters. Patients should avoid sources of magnetic and electromagnetic radiation to avoid possible underdetection, inappropriate sensing and/or therapy delivery, tissue damage, induction of an arrhythmia, device electrical reset, or device damage. Do not place transcutaneous defibrillation paddles directly over the device. Use of the device should not change the application of established anticoagulation protocols. Patients and their implanted systems must be screened to meet the following requirements to determine lead extenders, lead adaptors, or abandoned leads present; no broken leads or leads with intermittent electrical contact as confirmed by lead impedance history; the device must be operating within the projected service life; and the system must be implanted in the left or right pectoral region.

Potential Adverse Events or Potential Complications: Potential complications include, but are not limited to, rejection phenomena, erosion through the skin, muscle or nerve structure, oversensing, failure to detect and/or terminate arrhythmia episodes, acceleration of tachycardia, and surgical complications such as hematoma, infection, inflammation, and thrombosis. Potential lead complications include, but are not limited to, vascular damage, fibrosis, thrombosis, thrombolic and air embolism, cardiac perforation, heart wall rupture, cardiac tamponade, pericardial rub, infection, myocardial irritability, and pneumothorax. Other potential complications related to the lead may include lead dislodgement, lead conductor fracture, insulation failure, threshold elevation, or exit block. Potential MRI complications include, but are not limited to, lead electrode heating and tissue damage resulting in loss of sensing or capture or both, or induced currents on leads resulting in continuous capture, VT/VF, and/or hemodynamic collapse.

See the device manuals before performing an MRI Scan for detailed information regarding the implant procedure, indications, MRI conditions of use, contraindications, warnings, precautions, and potential complications. For further information, call Medtronic at 1-800-528-2518 and/or consult the Medtronic website at medtronic.com.

MDmedtronic Model 24970 CareLink SmartSync™ Device Manager Base and Associated Apps

Indications: The base is intended to be used as part of the CareLink SmartSync device manager system. Clinicians use the base to analyze the electrical performance of cardiac leads during device plant or outpatient follow-up. The base includes a wireless module that connects along with the app display to view, measure, and record live cardiac waveforms. The base is intended to be used by healthcare professionals only in operating environments under direct medical supervision.

Contraindications: The base is not intended for use as an external pulse generator (EPG) outside of the implant procedure. In addition, the patient’s age and medical condition may dictate the lead analyses appropriate for the patient.

See the CareLink SmartSync 24970 Technical Manual and 24977 Patient Connector Technical Manual before using the CareLink SmartSync device manager for detailed information regarding the procedure, indications, or intended uses, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-528-2518 and/or consult the Medtronic website at medtronic.com.

MDmedtronic Model 24967 Patient Connector and Associated Apps

Indications: The patient connector is intended to be used with Medtronic apps to interrogate, analyze, and/or program implantable Medtronic devices. The patient connector uses Bluetooth® technology to transmit that data to a Medtronic app for further processing. The patient connector is intended to be used by healthcare personnel only in a clinical or hospital environment.

Precautions: Security — Maintain adequate physical security of the patient connector to prevent unauthorized use of the device. In that case, that could lead to harm to patients. Bluetooth communication in the patient connector is encrypted for security. Medtronic inductive telemetry uses short-range communication to protect patient information. If the patient connector should fail, there is no risk of patient harm.

See the CareLink SmartSync 24967 Patient Connector Technical Manual before using the CareLink SmartSync device manager for detailed information regarding the procedure, indications, or intended uses, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-528-2518 and/or consult the Medtronic website at medtronic.com.

See the device manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, contact your local Medtronic representative or consult the Medtronic website at medtronic.com.

Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.

Medtronic

710 Medtronic Parkway
Minneapolis, MN 55432-5604
USA

medtronic.com

Toll-free in USA: 800.633.8766
Worldwide: +1.763.514.4000

Dec 2020

Medtronic, Minneapolis, MN. All Rights Reserved. Printed in USA. 05/2020

UC201801292d EN ©2020 Medtronic. Minneapolis, MN. All Rights Reserved. Printed in USA. 05/2020